The New England journal of medicine
-
Editorial Comment
No End to Uncertainty about Inhaled Glucocorticoids in Preterm Infants.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia.
Systemic glucocorticoids reduce the incidence of bronchopulmonary dysplasia among extremely preterm infants, but they may compromise brain development. The effects of inhaled glucocorticoids on outcomes in these infants are unclear. ⋯ Among extremely preterm infants, the incidence of bronchopulmonary dysplasia was lower among those who received early inhaled budesonide than among those who received placebo, but the advantage may have been gained at the expense of increased mortality. (Funded by the European Union and Chiesi Farmaceutici; ClinicalTrials.gov number, NCT01035190.).